吉非替尼靶向治疗NSCLC的有效性和安全性研究

Research on efficacy and safety of gefinitib targeted therapy on NSCLC

目的探讨吉非替尼靶向治疗非小细胞肺癌(NSCLC)的有效性和安全性。方法将2009年6月—2011年12月确诊的NSCLC患者96例随机分成2组:观察组48例,对照组48例。对照组静脉滴注多西他赛注射液治疗,观察组口服吉非替尼治疗。观察比较2组患者的临床疗效、生活质量评分、不良反应发生率。结果观察组总有效率为70.83%,高于对照组的50.00%(P<0.05);观察组患者的躯体功能、角色功能、情感功能、认知功能、总生活质量评分均优于对照组(P<0.05)。观察组粒细胞减少、血小板下降、恶心呕吐、腹泻、皮疹、瘙痒、肝肾毒性等不良反应发生率均少于对照组(P<0.05)。结论临床应用吉非替尼靶向治疗NSCLC的临床效果显著,不良反应少。

Objective To investigate the clinical significance of gefinitib for the treatment of non-small cell lung cancer （NSCLC） patients. Methods The 96 cases of NSCLC patients admitted to hospital from June 2009 to December 2011 were randomly divided into two groups, control group （ n = 48） and treatment group （ n = 48）. The control group was given docetaxel injection, but the treatment group was given gefinitib. The clinical efficacy, the QLQ-C30 scores and the incidence of adverse reactions in 2 groups was observed and ~ompared. Results The total effective rate was 70.83% in the treatment group, but the control group was 50.00%, so the total effective rate in the treatment group was significantly higher than that of the control group（ P 〈 0.05 ） ; the physical function, role function, emotional function, cognitive function, and overall QLQ- c30 scores in the treatment group was significantly better than that of the control group （ P 〈 0.05） ,the incidence of neutro- penia, thrombocytopenia, nausea, vomiting, diarrhea, rash, itching, stomatitis, liver and kidney toxicity in the treatment group was significantly tess than that of the control group （ P 〈 0.05）. Conclusion There is a significant clinical effect of gefinitib for the treatment of NSCLC patients.